1. Nair S, Bavaskar M, Abhishek PT, Singhavi H, Singh A, Shetty R, Joshi P (2024). Surgical management of patients with distant metastasized adenoid cystic carcinoma of the head and neck. Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology.

2. Sarma R, Kashyap L, Srikanth A, Mondal T, Kashyap Y, Nandhana R, Bondili SK, Bonda A, Nayak L, Chatterjee G, Jain H, Patkar N, Tembhare P, Subramanian P, Gujral S, Sengar M, Menon H, Nair R, Bagal B (2024). Real world outcomes with treatment free remission in chronic myeloid leukemia-Experience from a tertiary care cancer centre. Indian Journal of Hematology and Blood Transfusion.

3. Varghese R, Pal K, Gota V, Islam MF (2024). Colonic probiotic insufflation: clinical proposal for an economical game-changer for restoration of the gut microbiome in colorectal cancer and beyond. International Journal of Surgery. 110(5): 2515-2519.

4. Prabhash K, Saldanha E, Patil V, Bal M, Reddy P S, Sanjeev A, Kumar R, Poojary D, Noronha V, Menon N, Mittal N, Trivedi V, Nambiar K, Mishra R, Tanwar N, Malhotra R, Pange P, Gupta V, Veldore VH, Chougule A, Chaturvedi P, Dutt A, Chandrani P (2024). RET alterations differentiate molecular profile of medullary thyroid cancer. JCO Precision Oncology. 8:e2300622.

5. Gupta T, Mani S, Chatterjee A, Dasgupta A, Epari S, Chinnaswamy G (2024). Risk-stratification for treatment de-intensification in WNT-pathway medulloblastoma: finding the optimal balance between survival and quality of survivorship. Expert Review of Anticancer Therapy.
Thesis
Aaiyas Abdulhamid Mujawar. 2024. Developing in vivo bio-imaging methods using fungal luciferase. (LIFE09201704004) (Guide: Dr. Abhijit De)

GENT2 is a platform for exploring gene expression patterns across normal and tumor tissues.

Paul S, Konig MF, Pardoll DM, Bettegowda C, Papadopoulos N, Wright KM, Gabelli SB, Ho M, van Elsas A, Zhou S (2024). Cancer therapy with antibodies. Nature Reviews Cancer.

In 2013, Radium Ra 223 dichloride (Xofigo), which can bind with minerals in the bone and deliver radiation directly to bone tumors, was approved by FDA to treat metastatic, castration-resistant prostate cancer that has spread to bones.

2019 Advanced Centre for Treatment, Research and Education in Cancer (ACTREC)